Condition
Pervasive Development Disorders
Total Trials
4
Recruiting
0
Active
0
Completed
3
Success Rate
75.0%-12% vs avg
Key Insights
Highlights
Success Rate
75% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 42/100
Termination Rate
25.0%
1 terminated out of 4 trials
Success Rate
75.0%
-11.5% vs benchmark
Late-Stage Pipeline
50%
2 trials in Phase 3/4
Results Transparency
100%
3 of 3 completed with results
Key Signals
3 with results75% success
Data Visualizations
Phase Distribution
4Total
Not Applicable (1)
P 2 (1)
P 4 (2)
Trial Status
Completed3
Terminated1
Trial Success Rate
75.0%
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT01238575Phase 4CompletedPrimary
Guanfacine for the Treatment of Hyperactivity in Pervasive Developmental Disorder
NCT00205699Phase 4Completed
Metabolic Effects of Antipsychotics in Children
NCT01602016Phase 2Terminated
A Folinic Acid Intervention for Autism Spectrum Disorders
NCT00025779Not ApplicableCompleted
Methylphenidate in Children and Adolescents With Pervasive Developmental Disorders
Showing all 4 trials